Tech Bulletin Barbados
SEE OTHER BRANDS

Exploring the science and technology news of Barbados

Tech Bulletin Barbados: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Bulletin Barbados.

Press releases published on May 14, 2025

Jakub Leps Promoted to General Manager of Newsmatics Data Sciences

Jakub Leps Promoted to General Manager of Newsmatics Data Sciences

Leps to lead strategy and operations at the forefront of data innovation WASHINGTON, DC, UNITED STATES, May 14, 2025 /⁨EINPresswire.com⁩/ -- Newsmatics, a news technology company known for its suite of innovative digital media products, is proud to …

THE BANCORP 48 HOUR DEADLINE ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against The Bancorp, Inc. - TBBK

THE BANCORP 48 HOUR DEADLINE ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against The Bancorp, Inc. - TBBK

NEW ORLEANS, May 14, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until May 16, 2025 to file lead plaintiff applications in a securities class action lawsuit against The Bancorp, Inc. …

After iOS Traction, AI Pet Travel App Kruiz, Announces Android Launch

After iOS Traction, AI Pet Travel App Kruiz, Announces Android Launch

Irvine, California, May 14, 2025 (GLOBE NEWSWIRE) -- Co-founders Brad Pauer and Angela Le had confirmed—twice—that their dog could fly in-cabin on a trip to London. But a last-minute policy change at Heathrow Airport left them stranded, out thousands of …

Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results

Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results

CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 …

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using …

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean …

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using …

HP Inc. Declares Dividend

HP Inc. Declares Dividend

PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) has declared a cash dividend of $0.2894 per share on the company’s common stock. The dividend, the third in HP’s fiscal year 2025, is payable on July 2, 2025, to stockholders of record …

GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)

GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le …

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and  Provides Business Highlights

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN …

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

WILMINGTON, Del., May 14, 2025 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline …

Aterian Reports 2025 First Quarter Financial Results

Aterian Reports 2025 First Quarter Financial Results

SUMMIT, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products company, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”). The Company also provided an …

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million …

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim …

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by …

zSpace Reports First Quarter 2025 Financial Results

zSpace Reports First Quarter 2025 Financial Results

SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- zSpace (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leader in augmented and virtual reality solutions for education, is announcing its financial results for the three months ended March 31, 2025. “We are …

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax …

Korro to Participate in Upcoming Investor Conferences

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare Conference Ram …

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

-  Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD -  Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3 …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service